False-positive serum prostate-specific antigen values in a patient with non-Hodgkin lymphoma of the kidney.
Prostate-specific antigen (PSA) is the clinically most useful tumor marker for prostate cancer. Although false-positive elevations have been reported due to disease processes outside the prostate gland with the use of the polyclonal assay, such false-positive test results have been exceedingly rare with the use of the monoclonal assay. We report the case of a patient diagnosed with a B-cell lymphoma of the kidney and a significant elevation of serum PSA levels by monoclonal assay in the absence of either inflammatory or malignant prostate disease. PSA returned to normal during lymphoma-specific chemotherapy with a cyclophosphamide, mechlorethamine, vincristine, procarbazine, prednisone regimen. Possible explanations and clinical implications are discussed.
Djavan
B
B
Department of Surgery, University of Texas Southwestern Medical Center, Dallas, USA.
Keffer
J H
JH
Molberg
K
K
Roehrborn
C G
CG
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005189:False Positive Reactions; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D016393:Lymphoma, B-Cell / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood*; D014057:Tomography, X-Ray Computed
D017430:Prostate-Specific Antigen